Introduction: However, there has been a history of continuing 3TC/FTC in antiretroviral therapy (ART) regimens for some PLHIV with M184V/I because of the potential benefits of maintaining this mutation 5, 6 linked to impaired viral fitness and the finding that 3TC seems to retain some antiviral effect even in the presence of the M184V mutation 7.
Introduction: The HIV-1 reverse transcriptase M184V/I mutation has historically been common in people living with HIV (PLHIV) experiencing virological failure on regimens that contain lamivudine (3TC) or emtricitabine (FTC).
Introduction: The question of whether there is a benefit of maintaining 3TC/FTC in PLHIV with the M184V/I mutation remains relevant, particularly as there is current interest in dual-therapy regimens (including some containi
Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
Result: In addition, the OLA did not detect resistance to NNRTI in one participant with V106M and Y188C, or resistance to 3TC in four participants with M184I, as these mutations were not interrogated by the OLA.
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
PMID: 31965175
2020
The Journal of infectious diseases
Abstract: In RT, 9 nonpolymorphic TSMs occurred in >=10 persons: K40R, A62V, K70R, Y115F, Q151M, M184VI, S215Y.
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%).
Result: However, when we compared individual mutations we found that M184V/I (p = 0.015), Y188L (p = 0.008) and TAMs (p = 0.011) were significantly more common in Subtype A as compared to Subtype D and others.
Result: When we compared individual mutations within the NRTI class, M184V/I mutation had the highest prevalence of 120 (65.9%) among patients.
Discussion: However, M184V/I (67 (55.8%), p = 0.015), Y188L (9 (100%), p = 0.008) and TAMs (44 (51.8%),
HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.
Abstract: Antiretroviral resistance was detected in 21.5% of 93 pol sequences analyzed, with the M184I/V and K103N mutations that confer high-level resistance to NRTI and NNRTI, respectively, being the most frequent mutations.
Result: Among the 7 cases with NRTI mutations, the most common was M184I/V, which is known to confer high-level resistance to both emtricitabine (FTC) and 3TC.
Table: M184I
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Abstract: Major nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, M184I/V, D67N, T215F, and K70R/E were found.
Result: The predominant major NRTI mutation was M184I/V, while K103N
Discussion: Other mutations detected in this study, which have been shown to confer resistance to NRTIs, were M184I, T69N, L74I, M41L, K70R/E, T215Y/F, and K219E.
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
PMID: 32065630
2020
The Journal of antimicrobial chemotherapy
Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.
Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Conclusion: Our structures also explain a common mechanism for 3TC/ETV resistance by severe steric clash between the M184V/I (M204V/I in HBV) side-chain and the oxathiolane/methylene of boun
Result: M184V/I in HIV-1 RT has long been known as a critical 3TC-resistant-associated mutation in HIV-1.
Result: One possible solution to overcome M184V/I (M204V/I in HBV) resistance is to decrease composition for NRTIs that do not rely on the interactions with Met184.
Result: Thus, a M184V/I steric clash would likely occur when 3TC-TP tightly binds to the N-site, as observed in this study.
Result: Thus, a nearly identical ETV/3TC resistance mechanism appears to work for resistance to ETV and 3TC with M184I.
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Abstract: The mutation rate at 14 sites increased significantly at TF time point compared to baseline, with the most common DRMs comprising G190S/C, K65R, K101E/N/Q, M184 V/I, and V179D/I/A/T/E, ranging from 66.7 to 45.2%.
Result: The NRTI-associated DRMs detected at TF time point in descending order included K65R (57.1%), M184 V/I (47.6%), S68G (26.2%), A62V (14.3%), K70E/R (9.5%), and Y115F (9.5%).
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: Resistance to previous NNRTIs is heterogeneous, with resistance against first-generation NNRTIs (NVP and EFV) being often associated with the highly fit K103N substitution, whereas resistance against second-generation NNRTIs (ETR and RPV) is often linked to substitutions at position E138 together with the M184I NRTI-resistance substitution.
HIV mutation literature information.
PMID: 
2020
HIV medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT